Is NRSN or CRIS more profitable?

NeuroSense Therapeutics has a net margin of 0.00% compared to Curis' net margin of -80.29%. Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Curis -80.29% N/A -181.57%

Does the media prefer NRSN or CRIS?

In the previous week, Curis had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 6 mentions for Curis and 5 mentions for NeuroSense Therapeutics. Curis' average media sentiment score of 0.54 beat NeuroSense Therapeutics' score of 0.37 indicating that Curis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Curis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, NCEL or CRIS?

Curis has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Curis $9.44M 0.40 -$7.58M -$23.80 N/A

Is NCEL or CRIS more profitable?

NLS Pharmaceutics has a net margin of 0.00% compared to Curis' net margin of -80.29%. Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Curis -80.29% N/A -181.57%

Does the media prefer KTTA or CRIS?

In the previous week, Curis had 3 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 6 mentions for Curis and 3 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.44 beat Curis' score of 0.54 indicating that Pasithea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Curis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is APLT or CRIS more profitable?

Applied Therapeutics has a net margin of 0.00% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% Curis -80.29% N/A -181.57%

Which has stronger valuation and earnings, HIND or CRIS?

Curis has higher revenue and earnings than Vyome. Vyome is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vyome $320K 47.82 -$10.26M -$12.27 N/A Curis $9.44M 0.40 -$7.58M -$23.80 N/A

Is HIND or CRIS more profitable?

Curis has a net margin of -80.29% compared to Vyome's net margin of -3,024.84%. Curis' return on equity of 0.00% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Vyome -3,024.84% -197.33% -138.14% Curis -80.29% N/A -181.57%

Curis (CRIS) Competitors

$1.80 -0.07 (-3.74%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.84 +0.04 (+2.50%)

As of 08/14/2026 07:34 PM Eastern

Compare

CRIS vs. NRSN, NCEL, KTTA, APLT, and HIND

Should you buy Curis stock or one of its competitors? Curis's main competitors and comparable companies include NeuroSense Therapeutics (NRSN), NLS Pharmaceutics (NCEL), Pasithea Therapeutics (KTTA), Applied Therapeutics (APLT), and Vyome (HIND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Curis compare to NeuroSense Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Curis has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Curis	$9.44M	0.40	-$7.58M	-$23.80	N/A

1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Comparatively, 5.8% of Curis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

NeuroSense Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 1,775.97%. Curis has a consensus price target of $43.00, indicating a potential upside of 2,288.89%. Given Curis' higher probable upside, analysts clearly believe Curis is more favorable than NeuroSense Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Curis had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 6 mentions for Curis and 5 mentions for NeuroSense Therapeutics. Curis' average media sentiment score of 0.54 beat NeuroSense Therapeutics' score of 0.37 indicating that Curis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Curis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroSense Therapeutics has a net margin of 0.00% compared to Curis' net margin of -80.29%.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Curis	-80.29%	N/A	-181.57%

NeuroSense Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, Curis has a beta of 3.13, meaning that its stock price is 213% more volatile than the broader market.

Summary

Curis beats NeuroSense Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Curis compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

NLS Pharmaceutics presently has a consensus price target of $23.00, suggesting a potential upside of 586.57%. Curis has a consensus price target of $43.00, suggesting a potential upside of 2,288.89%. Given Curis' higher probable upside, analysts clearly believe Curis is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Curis has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Curis	$9.44M	0.40	-$7.58M	-$23.80	N/A

In the previous week, Curis had 5 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 6 mentions for Curis and 1 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.87 beat Curis' score of 0.54 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company	Overall Sentiment
NLS Pharmaceutics	Very Positive
Curis	Positive

NLS Pharmaceutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Curis has a beta of 3.13, indicating that its stock price is 213% more volatile than the broader market.

30.0% of Curis shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Comparatively, 5.8% of Curis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

NLS Pharmaceutics has a net margin of 0.00% compared to Curis' net margin of -80.29%.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Curis	-80.29%	N/A	-181.57%

Summary

Curis beats NLS Pharmaceutics on 6 of the 11 factors compared between the two stocks.

How does Curis compare to Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Pasithea Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Curis has a beta of 3.13, suggesting that its stock price is 213% more volatile than the broader market.

Curis has higher revenue and earnings than Pasithea Therapeutics. Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Curis	$9.44M	0.40	-$7.58M	-$23.80	N/A

Pasithea Therapeutics has a net margin of 0.00% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Curis	-80.29%	N/A	-181.57%

Pasithea Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 524.35%. Curis has a consensus target price of $43.00, indicating a potential upside of 2,288.89%. Given Curis' higher possible upside, analysts clearly believe Curis is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 5.8% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Curis had 3 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 6 mentions for Curis and 3 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.44 beat Curis' score of 0.54 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Curis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Curis beats Pasithea Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Curis compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Applied Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Curis has a consensus price target of $43.00, indicating a potential upside of 2,288.89%. Given Curis' higher probable upside, analysts clearly believe Curis is more favorable than Applied Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Applied Therapeutics has a net margin of 0.00% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Curis	-80.29%	N/A	-181.57%

Curis has higher revenue and earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Curis	$9.44M	0.40	-$7.58M	-$23.80	N/A

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by company insiders. Comparatively, 5.8% of Curis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Curis had 6 more articles in the media than Applied Therapeutics. MarketBeat recorded 6 mentions for Curis and 0 mentions for Applied Therapeutics. Curis' average media sentiment score of 0.54 beat Applied Therapeutics' score of 0.00 indicating that Curis is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Curis	Positive

Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Curis has a beta of 3.13, meaning that its share price is 213% more volatile than the broader market.

Summary

Curis beats Applied Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Curis compare to Vyome?

Vyome (NASDAQ:HIND) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Curis has higher revenue and earnings than Vyome. Vyome is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	47.82	-$10.26M	-$12.27	N/A
Curis	$9.44M	0.40	-$7.58M	-$23.80	N/A

Vyome has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Curis has a beta of 3.13, indicating that its stock price is 213% more volatile than the broader market.

Vyome currently has a consensus target price of $15.00, indicating a potential upside of 588.07%. Curis has a consensus target price of $43.00, indicating a potential upside of 2,288.89%. Given Curis' higher probable upside, analysts clearly believe Curis is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Curis has a net margin of -80.29% compared to Vyome's net margin of -3,024.84%. Curis' return on equity of 0.00% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-3,024.84%	-197.33%	-138.14%
Curis	-80.29%	N/A	-181.57%

22.1% of Vyome shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 33.0% of Vyome shares are owned by insiders. Comparatively, 5.8% of Curis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Curis had 4 more articles in the media than Vyome. MarketBeat recorded 6 mentions for Curis and 2 mentions for Vyome. Vyome's average media sentiment score of 1.47 beat Curis' score of 0.54 indicating that Vyome is being referred to more favorably in the media.

Company	Overall Sentiment
Vyome	Positive
Curis	Positive

Summary

Curis beats Vyome on 9 of the 16 factors compared between the two stocks.

Get Curis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRIS vs. The Competition

Export

Metric	Curis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.91M	$3.71B	$7.02B	$13.06B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-0.08	10.78	271.27	25.33
Price / Sales	0.40	1,245.43	583.72	76.93
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	0.21	16.78	12.92	6.25
Net Income	-$7.58M	-$13.32M	$3.45B	$347.82M
7 Day Performance	-55.22%	1.76%	1.15%	1.08%
1 Month Performance	-61.95%	1.14%	1.37%	0.82%
1 Year Performance	-95.08%	54.35%	62.53%	20.99%

Curis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRIS Curis	2.4116 of 5 stars	$1.80 -3.7%	$43.00 +2,288.9%	-94.6%	$3.91M	$9.44M	N/A	60	News Coverage Earnings Report Analyst Downgrade Gap Down
NRSN NeuroSense Therapeutics	3.3429 of 5 stars	$0.47 -3.1%	$8.50 +1,712.4%	-61.3%	$17.71M	N/A	N/A	10	News Coverage
NCEL NLS Pharmaceutics	2.8251 of 5 stars	$3.21 -1.2%	$23.00 +616.5%	-87.2%	$17.17M	N/A	N/A	6	Positive News Gap Down
KTTA Pasithea Therapeutics	3.8753 of 5 stars	$0.48 +0.8%	$3.00 +527.6%	-31.6%	$15.97M	N/A	N/A	3	News Coverage Positive News Earnings Report
APLT Applied Therapeutics	1.5027 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRIS) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Curis (CRIS) Competitors

CRIS vs. NRSN, NCEL, KTTA, APLT, and HIND

How does Curis compare to NeuroSense Therapeutics?

Summary

How does Curis compare to NLS Pharmaceutics?

Summary

How does Curis compare to Pasithea Therapeutics?

Summary

How does Curis compare to Applied Therapeutics?

Summary

How does Curis compare to Vyome?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS vs. The Competition

Curis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Curis (CRIS) Competitors

CRIS vs. NRSN, NCEL, KTTA, APLT, and HIND

How does Curis compare to NeuroSense Therapeutics?

Which has better valuation and earnings, NRSN or CRIS?

Do institutionals and insiders believe in NRSN or CRIS?

Do analysts rate NRSN or CRIS?

Does the media prefer NRSN or CRIS?

Is NRSN or CRIS more profitable?

Which has more risk & volatility, NRSN or CRIS?

Summary

How does Curis compare to NLS Pharmaceutics?

Do analysts prefer NCEL or CRIS?

Which has better earnings and valuation, NCEL or CRIS?

Does the media refer more to NCEL or CRIS?

Which has more risk & volatility, NCEL or CRIS?

Do insiders and institutionals hold more shares of NCEL or CRIS?

Is NCEL or CRIS more profitable?

Summary

How does Curis compare to Pasithea Therapeutics?

Which has more volatility and risk, KTTA or CRIS?

Which has preferable valuation & earnings, KTTA or CRIS?

Is KTTA or CRIS more profitable?

Do analysts recommend KTTA or CRIS?

Do institutionals and insiders have more ownership in KTTA or CRIS?

Does the media prefer KTTA or CRIS?

Summary

How does Curis compare to Applied Therapeutics?

Do analysts rate APLT or CRIS?

Is APLT or CRIS more profitable?

Which has stronger earnings & valuation, APLT or CRIS?

Do insiders and institutionals have more ownership in APLT or CRIS?

Does the media prefer APLT or CRIS?

Which has more risk and volatility, APLT or CRIS?

Summary

How does Curis compare to Vyome?

Which has stronger valuation and earnings, HIND or CRIS?

Which has more risk and volatility, HIND or CRIS?

Do analysts prefer HIND or CRIS?

Is HIND or CRIS more profitable?

Do insiders & institutionals believe in HIND or CRIS?

Does the media refer more to HIND or CRIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS vs. The Competition

Curis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools